Arcus Biosciences Inc. research snapshot
RCUS AI stock analysis currently reads Arcus Biosciences as a clinical-stage biopharmaceutical company developing cancer immunotherapies, with a pipeline led by Casdatifan (HIF-2a inhibitor), Domvanalimab (anti-TIGIT), and Zimberelimab (anti-PD-1). The analysis uses a scenario framework, not a certain price prediction. At the August 4, 2026 cutoff, the latest verified close was $27.62 on August 3, market capitalization was about $3.47 billion, and the main question was whether upcoming Q2 2026 results on August 5 and the kidney cancer data calendar can justify a valuation that has more than tripled over the past year. TTM revenue of $236 million is mostly collaboration income, the TTM net loss is about $369 million, and cash plus investments of $822 million funds the pipeline into key readouts. This is informational research and not investment advice.
Current price
$27.62
Market cap
$3.47 billion
AI score
54 / 100
Rating
Speculative biotech with advancing kidney cancer franchise, pre-profit
Trend status
Strong one-year uptrend up 201%, consolidating below the late-June high near $31.74
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Arcus discovers and develops cancer therapies targeting immune checkpoint, hypoxia, adenosine, and CD39 pathways. Revenue comes from collaboration and license payments, not product sales, and the company is not yet profitable. | Medium |
| Moat | The moat is potential, not proven. Arcus holds IP around HIF-2a, anti-TIGIT, CD73, and CD39 programs, but competitive differentiation depends on clinical data versus larger players like Merck, BMS, AstraZeneca, and Roche. | Low-medium |
| Management | Co-founder CEO Terry Rosen leads an experienced oncology team that has secured collaborations with AstraZeneca, BMS, Summit Therapeutics, and AVEO Oncology. Share count rose 22.5% year over year, so dilution discipline matters as cash burn continues. | Medium |
| Financial trend | TTM revenue of $236 million, up 67% year over year, mainly from collaboration income. TTM net loss is about $369 million and TTM free cash flow is about negative $489 million. Cash plus investments of $822 million at March 31, 2026 funds operations into key catalysts. | Medium |
| Valuation | At 14.7x TTM revenue and 6.6x book value, valuation reflects pipeline potential rather than current earnings. The stock must deliver positive clinical data and manage cash burn to justify the multiple. | Low-medium |
| Technical trend | RCUS is up 201% over the past year and trades below its 52-week high of $31.74 set on June 30, 2026. The stock recently pulled back from that high and sits near the 50-day moving average of $26.90. | Medium |
| Risk level | High. Clinical trial failure, regulatory delay, competition from larger biopharma, cash burn of about $489 million TTM, dilution risk, and binary catalyst dependence are all material risk factors. | High |
| AI confidence | Medium confidence for mapping the pipeline, financial position, and partnership structure. Lower confidence for predicting clinical trial outcomes, the August 5 earnings reaction, or stock price moves. | Medium data confidence |
| Investment certainty | Low to medium certainty. The business is pre-product-revenue and carries typical clinical-stage biotech binary risk. | Low-medium |
RCUS AI stock forecast
The RCUS AI stock forecast uses scenario ranges around the $27.62 cutoff price rather than a point target. The bullish case requires continued positive Casdatifan data across the new kidney cancer collaborations and strong Q2 results; the base case assumes mixed readouts with the stock trading near analyst ranges; the bearish case assumes clinical setbacks, financing concerns, or a disappointing August 5 report.
$40 to $50
More likely if Q2 2026 results on August 5 reassure on cash runway, Casdatifan keeps showing best-in-class potential in kidney cancer, the BMS, Summit, and AVEO collaborations expand, and the stock approaches the higher analyst targets near $46 to $47.
$26 to $38
More likely if data are mixed but not negative, the company maintains its cash position and partnership structure, and the stock trades within the consensus target range with a median near $38 and an average near $36.83.
$14 to $24
More likely if a key trial disappoints, a large partner withdraws, equity dilution is needed to extend the runway, or the August 5 report misses expectations. Cash per share of about $5.12 provides a partial floor but does not protect against clinical setbacks.
RCUS AI technical analysis
RCUS AI technical analysis starts from the $27.62 close on August 3, 2026 used for this August 4 static page. The stock is in a strong medium-term uptrend, up 201% over one year, but has pulled back roughly 13% from the 52-week high of $31.74 reached on June 30, 2026. Barchart rated the technical opinion at 80% Buy with a weakening short-term outlook. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.62 | Latest verified close used for this page, from August 3, 2026, the last trading day before the data cutoff. |
| Near support | $26.90 to $27.04 | The 50-day moving average of $26.90 overlaps the first support level per Barchart turning points. Holding above this zone keeps the short-term trend intact. |
| Secondary support | $25.91 | Third support level per Barchart. A close below $25.91 would signal a deeper pullback and weaken the technical picture. |
| Near resistance | $28.17 to $29.30 | First through third resistance zones per Barchart turning points. Reclaiming $28.17 would suggest renewed buying interest after the pullback. |
| Key resistance | $31.74 | The 52-week high reached on June 30, 2026. A close above this level with volume would confirm a resumption of the uptrend. |
| 200-day moving average | $23.34 | The long-term trend reference. The price remains well above the 200-day average, consistent with a medium-term uptrend. |
| Momentum | Mixed, recovering from the June high | RCUS gained about 7.6% over three months and 201% over one year but fell about 8.9% in the past month as it pulled back from the June peak. RSI near 48 is neutral. |
| Volume | About 856K shares on August 3 | Volume of about 856K was below the 20-day average near 1.01 million, suggesting the recent pullback lacks heavy distribution pressure. |
| Volatility | IV near 84%, HV near 59% | Implied volatility of 83.89% and historical volatility of 58.75% reflect the extreme price risk around the August 5 earnings date. The options market implied an expected move of about 3% over 18 days. |
| Invalidation | Close below $25.91, then $23.00 | A close below $25.91 weakens the near-term picture. A break below the Fibonacci 61.8% retracement near $23.00 would challenge the medium-term uptrend. |
RCUS AI trading strategy
The RCUS AI trading strategy is a rules-based research framework, not personalized advice. It combines pipeline and earnings calendar awareness, technical confirmation, position sizing for binary risk, and clear invalidation levels. Due to the extreme volatility around the August 5 Q2 report, risk management is paramount.
The near-term catalysts are the Q2 2026 results and conference call on August 5, plus Casdatifan data across the new kidney cancer collaborations with BMS, Summit, and AVEO. Price tends to move sharply on earnings and data news cycles.
Reduce position size before the August 5 report and before binary data readouts. Biotech events can produce 30-50% moves, and the TTM free cash outflow of about $489 million makes financing announcements possible.
If RCUS holds $26.90 to $27.04 support and reclaims $28.17 resistance with volume, momentum could resume toward the June high near $31.74. Confirm with rising moving averages and improving volume.
A failed recovery or close below $25.91 should invalidate the setup. Do not chase the stock far above $28.17 without confirmation given the recent pullback from the high.
Track Casdatifan and Domvanalimab clinical updates, the Q2 2026 cash position, quarterly R&D spend, share count changes, partnership expansions with BMS, Summit, and AVEO, and analyst coverage changes.
Reduce exposure if cash runway shortens without a financing plan, if share dilution accelerates beyond the 22.5% year-over-year increase, or if key partnership activity signals reduced commitment.
Investment research summary
Arcus Biosciences discovers and develops cancer immunotherapies targeting immune checkpoint, hypoxia, adenosine, and CD39 pathways, currently pre-revenue from product sales and funded by partnership income and equity financing.
Arcus holds intellectual property around HIF-2a inhibition, anti-TIGIT, CD73, and CD39 programs. Competitive differentiation depends on clinical data versus large biopharma programs from Merck, BMS, AstraZeneca, and Roche.
The thesis can fail if Casdatifan or Domvanalimab clinical data disappoint, a partner like BMS or AstraZeneca withdraws, cash burn forces dilutive financing, or competing therapies reach the market first with better profiles.
Co-founder and CEO Terry Rosen leads an experienced oncology team that has secured collaborations with AstraZeneca, BMS, Summit Therapeutics, and AVEO Oncology. Capital allocation and pipeline prioritization are key monitoring areas given the 22.5% year-over-year share increase.
Cancer immunotherapy is a large and growing field. Arcus targets multiple pathways in indications with high unmet need, but competition from well-funded large pharma is intense and the kidney cancer landscape is increasingly crowded.
At $27.62, a $3.47 billion market cap, and no product earnings, the stock prices in meaningful pipeline success. Price to sales of 14.7x TTM is above its own history, and margin of safety is low given the binary nature of clinical-stage biotech investing.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RCUS price | $27.62 close on August 3, 2026 | StockAnalysis and Google Finance quote snapshots | August 4, 2026 |
| Market capitalization | $3.47 billion, verified as $27.62 x 125.77 million shares with 0.11% deviation | StockAnalysis and financial_rigor.py | August 4, 2026 |
| TTM revenue | $236 million, up 67% year over year | StockAnalysis statistics (Fiscal.ai) | August 4, 2026 |
| TTM net income | -$369 million | StockAnalysis statistics (Fiscal.ai) | August 4, 2026 |
| Cash and short-term investments | $822 million at March 31, 2026 | StockAnalysis balance sheet (Fiscal.ai) | August 4, 2026 |
| Enterprise value | $2.83 billion, consistent with $3.47 billion market cap minus about $644 million net cash | StockAnalysis and financial_rigor.py | August 4, 2026 |
| Price to sales (TTM) | 14.72x | StockAnalysis and financial_rigor.py verification | August 4, 2026 |
| Analyst consensus | Average target $36.83, median $38, range $22 to $47, consensus Strong Buy from 13 analysts | StockAnalysis forecast and Google Finance analyst data | August 4, 2026 |
| 52-week range | $8.88 to $31.74 | StockAnalysis and Google Finance | August 4, 2026 |
| Beta (5Y monthly) | 0.80 | StockAnalysis and Google Finance | August 4, 2026 |
| Valuation math | PE: negative (no earnings), PB: 6.61x, PS: 14.72x, ROE: -69.95% from financial_rigor.py | financial_rigor.py valuation verification and StockAnalysis | August 4, 2026 |
This RCUS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available data as of August 4, 2026 and can be wrong. Clinical-stage biotech investments carry a high risk of loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
